Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 New frontiers of HCV therapy in HIV/HCV co-infection.

Literature DB >> 20563864

New frontiers of HCV therapy in HIV/HCV co-infection.

Abstract

Hepatitis C virus (HCV) leads to disproportionate morbidity and mortality in the HIV-positive population. A new era of anti-HCV therapeutics is emerging, with many direct antiviral agents and immunomodulating drugs in clinical development. This review discusses HCV treatments in development, with special attention to four agents being studied actively among HIV/HCV-co-infected persons.

Entities: Chemical

Mesh：

Substances：

Year: 2010 PMID： 20563864 DOI： 10.1007/s11904-010-0051-7

Source DB: PubMed Journal: Curr HIV/AIDS Rep ISSN： 1548-3568 Impact factor: 5.495

22 in total

1. Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide.

Authors: Jean-Francois Rossignol; Asem Elfert; Emmet B Keeffe
Journal: J Clin Gastroenterol Date: 2010-08 Impact factor: 3.062

2. The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation.

Authors: Menashe Elazar; Michael Liu; Sean A McKenna; Ping Liu; Elizabeth A Gehrig; Joseph D Puglisi; Jean-François Rossignol; Jeffrey S Glenn
Journal: Gastroenterology Date: 2009-08-04 Impact factor: 22.682

3. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study.

Authors: Hendrik W Reesink; Stefan Zeuzem; Christine J Weegink; Nicole Forestier; Andre van Vliet; Jeroen van de Wetering de Rooij; Lindsay McNair; Susan Purdy; Robert Kauffman; John Alam; Peter L M Jansen
Journal: Gastroenterology Date: 2006-10 Impact factor: 22.682

4. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.

Authors: Robert Flisiak; Saya V Feinman; Maciej Jablkowski; Andrzej Horban; Wieslaw Kryczka; Małgorzata Pawlowska; Jenny E Heathcote; Giuseppe Mazzella; Carmen Vandelli; Valérie Nicolas-Métral; Pierre Grosgurin; Jorge S Liz; Pietro Scalfaro; Hervé Porchet; Raf Crabbé
Journal: Hepatology Date: 2009-05 Impact factor: 17.425

5. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.

Authors: Christoph Sarrazin; Tara L Kieffer; Doug Bartels; Brian Hanzelka; Ute Müh; Martin Welker; Dennis Wincheringer; Yi Zhou; Hui-May Chu; Chao Lin; Christine Weegink; Henk Reesink; Stefan Zeuzem; Ann D Kwong
Journal: Gastroenterology Date: 2007-02-21 Impact factor: 22.682

6. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

Authors: Christophe Hézode; Nicole Forestier; Geoffrey Dusheiko; Peter Ferenci; Stanislas Pol; Tobias Goeser; Jean-Pierre Bronowicki; Marc Bourlière; Shahin Gharakhanian; Leif Bengtsson; Lindsay McNair; Shelley George; Tara Kieffer; Ann Kwong; Robert S Kauffman; John Alam; Jean-Michel Pawlotsky; Stefan Zeuzem
Journal: N Engl J Med Date: 2009-04-30 Impact factor: 91.245

Review 7. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?

Authors: Stefan Zeuzem
Journal: Ann Intern Med Date: 2004-03-02 Impact factor: 25.391

8. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.

Authors: Liangjun Lu; Tami J Pilot-Matias; Kent D Stewart; John T Randolph; Ron Pithawalla; Wenping He; Peggy P Huang; Larry L Klein; Hongmei Mo; Akhteruzzaman Molla
Journal: Antimicrob Agents Chemother Date: 2004-06 Impact factor: 5.191

9. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.

Authors: Brent E Korba; Menashe Elazar; Ping Lui; Jean-François Rossignol; Jeffrey S Glenn
Journal: Antimicrob Agents Chemother Date: 2008-08-18 Impact factor: 5.191

10. Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir.

Authors: Dale J Kempf; Cheri Klein; Hui-Ju Chen; Larry L Klein; Clinton Yeung; John T Randolph; Yau Y Lau; Linda E Chovan; Zhiwen Guan; Lisa Hernandez; Teresa M Turner; Peter J Dandliker; Kennan C Marsh
Journal: Antivir Chem Chemother Date: 2007

1 in total

Review 1. Mixing the right hepatitis C inhibitor cocktail.

Authors: Michael A Gelman; Jeffrey S Glenn
Journal: Trends Mol Med Date: 2010-11-23 Impact factor: 11.951

1 in total